Insmed Incorporated (NASDAQ:INSM) COO Sells $3,689,444.50 in Stock

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 45,605 shares of Insmed stock in a transaction that occurred on Thursday, February 6th. The shares were sold at an average price of $80.90, for a total transaction of $3,689,444.50. Following the sale, the chief operating officer now owns 189,157 shares in the company, valued at $15,302,801.30. This represents a 19.43 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Roger Adsett also recently made the following trade(s):

• On Tuesday, January 14th, Roger Adsett sold 1,457 shares of Insmed stock. The shares were sold at an average price of $68.72, for a total transaction of $100,125.04.
• On Friday, January 10th, Roger Adsett sold 4,902 shares of Insmed stock. The stock was sold at an average price of $63.68, for a total transaction of $312,159.36.
• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The shares were sold at an average price of $65.95, for a total value of $161,181.80.

Insmed Stock Down 1.0 %

NASDAQ:INSM opened at $79.95 on Monday. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The stock has a 50 day moving average of $72.88 and a 200-day moving average of $73.09. The firm has a market capitalization of $14.30 billion, a PE ratio of -14.41 and a beta of 1.11. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $82.04.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Steward Partners Investment Advisory LLC lifted its stake in Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 163 shares during the last quarter. V Square Quantitative Management LLC acquired a new stake in shares of Insmed in the 3rd quarter worth about $30,000. GAMMA Investing LLC increased its holdings in shares of Insmed by 71.3% in the 3rd quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 224 shares during the period. Spire Wealth Management bought a new stake in Insmed in the 4th quarter valued at about $47,000. Finally, Exchange Traded Concepts LLC boosted its stake in Insmed by 522.5% during the 3rd quarter. Exchange Traded Concepts LLC now owns 747 shares of the biopharmaceutical company’s stock valued at $55,000 after purchasing an additional 627 shares during the period.

Analysts Set New Price Targets

Several research firms recently commented on INSM. Morgan Stanley boosted their price target on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday. Truist Financial reiterated a “buy” rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. lifted their price target on shares of Insmed from $83.00 to $92.00 and gave the stock an “overweight” rating in a research note on Friday. HC Wainwright reiterated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. Finally, Guggenheim boosted their target price on shares of Insmed from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Friday. One analyst has rated the stock with a sell rating and sixteen have assigned a buy rating to the company. Based on data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $85.00.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.